Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Toby A Eyre

Showing results (51-60 of 163) with videos related to

Pageof 17
Sort By:
British Journal of Haematology|August 11, 2024
Central nervous system prophylaxis in large B-cell lymphoma: A British Society for Haematology Good Practice PaperMatthew R Wilson, Kate Cwynarski, Toby A Eyre, et al.
Ejhaem|February 26, 2024
Complete response of mantle cell lymphoma with central nervous system involvement at diagnosis with acalabrutinib - Case reportAisling Barrett, Toby A Eyre, Shaheel Bhuva, et al.
Blood Advances|May 7, 2021
Impact of R-CHOP dose intensity on survival outcomes in diffuse large B-cell lymphoma: a systematic reviewEdward J Bataillard, Chan Yoon Cheah, Matthew J Maurer, et al.
British Journal of Haematology|February 28, 2015
A phase II trial of AZD1152 in relapsed/refractory diffuse large B-cell lymphomaGraham P Collins, Toby A Eyre, Kim M Linton, et al.
Journal of Medical Economics|July 15, 2026
An unanchored matching-adjusted indirect comparison of the efficacy of zanubrutinib versus ibrutinib for the treatment of relapsed/refractory mantle-cell lymphomaToby A Eyre, Leyla Mohseninejad, Lianne Barnieh, et al.
Hematology (Amsterdam, Netherlands)|February 8, 2022
Outcomes of anti-CD38 isatuximab plus pomalidomide and dexamethasone in five relapsed myeloma patients with prior exposure to anti-C38 daratumumab: case seriesFaouzi Djebbari, Matt Poynton, Gina Sangha, et al.
British Journal of Haematology|February 23, 2018
Idelalisib-rituximab induces durable remissions in TP53 disrupted B-PLL but results in significant toxicity: updated results of the UK-wide compassionate use programmeToby A Eyre, Christopher P Fox, Ali Boden, et al.
Plos One|February 22, 2020
Treatment-free interval as an additional measure of efficacy in a large UK dataset of transplant ineligible myeloma patientsFaouzi Djebbari, Faye A Sharpley, Susan McLain-Smith, et al.
Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology|March 15, 2013
Mumps virus encephalomyelitis in a 19-year old male patient with an undefined severe combined immunodeficiency post-haematopoietic bone marrow transplantation: a rare fatal complicationToby A Eyre, Emanuela Pelosi, Stephen McQuaid, et al.
BMC Cancer|May 22, 2019
The STELLAR trial protocol: a prospective multicentre trial for Richter's syndrome consisting of a randomised trial investigation CHOP-R with or without acalabrutinib for newly diagnosed RS and a single-arm platform study for evaluation of novel agents in relapsed diseaseNiamh Appleby, Toby A Eyre, Maite Cabes, et al.
Pageof 17

Showing results (51-60 of 163) with videos related to

Sort By:
Pageof 17
British Journal of Haematology|August 11, 2024
Central nervous system prophylaxis in large B-cell lymphoma: A British Society for Haematology Good Practice PaperMatthew R Wilson, Kate Cwynarski, Toby A Eyre, et al.
Ejhaem|February 26, 2024
Complete response of mantle cell lymphoma with central nervous system involvement at diagnosis with acalabrutinib - Case reportAisling Barrett, Toby A Eyre, Shaheel Bhuva, et al.
Blood Advances|May 7, 2021
Impact of R-CHOP dose intensity on survival outcomes in diffuse large B-cell lymphoma: a systematic reviewEdward J Bataillard, Chan Yoon Cheah, Matthew J Maurer, et al.
British Journal of Haematology|February 28, 2015
A phase II trial of AZD1152 in relapsed/refractory diffuse large B-cell lymphomaGraham P Collins, Toby A Eyre, Kim M Linton, et al.
Journal of Medical Economics|July 15, 2026
An unanchored matching-adjusted indirect comparison of the efficacy of zanubrutinib versus ibrutinib for the treatment of relapsed/refractory mantle-cell lymphomaToby A Eyre, Leyla Mohseninejad, Lianne Barnieh, et al.
Hematology (Amsterdam, Netherlands)|February 8, 2022
Outcomes of anti-CD38 isatuximab plus pomalidomide and dexamethasone in five relapsed myeloma patients with prior exposure to anti-C38 daratumumab: case seriesFaouzi Djebbari, Matt Poynton, Gina Sangha, et al.
British Journal of Haematology|February 23, 2018
Idelalisib-rituximab induces durable remissions in TP53 disrupted B-PLL but results in significant toxicity: updated results of the UK-wide compassionate use programmeToby A Eyre, Christopher P Fox, Ali Boden, et al.
Plos One|February 22, 2020
Treatment-free interval as an additional measure of efficacy in a large UK dataset of transplant ineligible myeloma patientsFaouzi Djebbari, Faye A Sharpley, Susan McLain-Smith, et al.
Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology|March 15, 2013
Mumps virus encephalomyelitis in a 19-year old male patient with an undefined severe combined immunodeficiency post-haematopoietic bone marrow transplantation: a rare fatal complicationToby A Eyre, Emanuela Pelosi, Stephen McQuaid, et al.
BMC Cancer|May 22, 2019
The STELLAR trial protocol: a prospective multicentre trial for Richter's syndrome consisting of a randomised trial investigation CHOP-R with or without acalabrutinib for newly diagnosed RS and a single-arm platform study for evaluation of novel agents in relapsed diseaseNiamh Appleby, Toby A Eyre, Maite Cabes, et al.
Pageof 17